World's Best Scientists 2026 revealed!
Award Badge
Medicine
Germany
2026

D-Index & Metrics

Medicine

D-Index
143
Citations
88761
World Ranking
1491
National Ranking
71

Michael Hallek publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Michael Hallek sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,231 publications — 97th percentile

97% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Michael Hallek D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Michael Hallek sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 143 D-Index — 93rd percentile

93% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Medicine in Germany Leader Award
  • 2023 - Research.com Medicine in Germany Leader Award
  • 2011 - German National Academy of Sciences Leopoldina - Deutsche Akademie der Naturforscher Leopoldina – Nationale Akademie der Wissenschaften Internal Medicine and Dermatology

Overview

Michael Hallek is affiliated with the University of Cologne in Germany and specializes in the field of Medicine with a significant focus on Genetics, Pathology and Forensic Medicine, Immunology, Oncology, and Molecular Biology. Their body of work comprises 686 publications in Medicine, with subfield contributions including 191 in Genetics, 126 in Pathology and Forensic Medicine, 125 in Immunology, 81 in Oncology, and 49 in Molecular Biology.

They have contributed extensively to topics involving Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Immunodeficiency and Autoimmune Disorders, SARS-CoV-2 and COVID-19 Research, CAR-T cell therapy research, Advanced Breast Cancer Therapies, and Chronic Myeloid Leukemia Treatments. The count of publications per topic includes 360 on Chronic Lymphocytic Leukemia Research, 248 on Lymphoma Diagnosis and Treatment, 140 on Immunodeficiency and Autoimmune Disorders, 46 on SARS-CoV-2 and COVID-19 Research, 46 on CAR-T cell therapy research, 38 on Advanced Breast Cancer Therapies, and 36 on Chronic Myeloid Leukemia Treatments.

Frequent publication venues for Michael Hallek include Blood, Hematological Oncology, HemaSphere, Der Internist, and bioRxiv (Cold Spring Harbor Laboratory) with 75, 25, 23, 17, and 11 publications respectively.

Their frequent co-authors consist of Kirsten Fischer, Barbara Eichhorst, Stephan Stilgenbauer, Eugen Tausch, and Sandra Robrecht, reflecting a collaborative research environment.

Significant recent publications by Michael Hallek include:

  • "Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures" (2021) in American Journal of Hematology
  • "Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study" (2021) in The Lancet Regional Health - Europe
  • "COVID-19 associated pulmonary aspergillosis" (2020) in Mycoses
  • "Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up" (2020) in Annals of Oncology
  • "Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial" (2020) in The Lancet Oncology

Michael Hallek was awarded membership in the German National Academy of Sciences Leopoldina in 2011, recognizing contributions in Internal Medicine and Dermatology.

Best Publications

  • Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

    Michael Hallek;Bruce D. Cheson;Daniel Catovsky;Federico Caligaris-Cappio

  • Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

    Michael Hallek;K. Fischer;Gunter Fingerle-Rowson;A.M. Fink

  • Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

    Richard R. Furman;Jeff P. Sharman;Steven E. Coutre;Bruce D. Cheson

  • Comprehensive genomic profiles of small cell lung cancer

    Julie George;Jing Shan Lim;Se Jin Jang;Yupeng Cun

  • Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

    Valentin Goede;Kirsten Fischer;Raymonde Busch;Anja Engelke

  • iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

    Michael Hallek;Bruce D. Cheson;Daniel Catovsky;Federico Caligaris-Cappio

  • Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

    Martin Peifer;Lynnette Fernández-Cuesta;Martin L. Sos;Julie George

  • Mutations driving CLL and their evolution in progression and relapse.

    Dan A. Landau;Eugen Tausch;Amaro N. Taylor-Weiner;Chip Stewart

  • Real-time single-molecule imaging of the infection pathway of an adeno-associated virus.

    Georg Seisenberger;Martin U. Ried;Thomas Endreß;Hildegard Büning

  • Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

    Jonathan Weiss;Martin L. Sos;Danila Seidel;Martin Peifer

  • Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process

    M Hallek;P L Bergsagel;K C Anderson

  • Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.

    Barbara F. Eichhorst;Raymonde Busch;Georg Hopfinger;Rita Pasold

  • Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

    Stephan Stilgenbauer;Barbara Eichhorst;Johannes Schetelig;Steven Coutre

  • Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

    Kirsten Fischer;Othman Al-Sawaf;Jasmin Bahlo;Anna Maria Fink

  • Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

    Andreas Engert;Heinz Haverkamp;Carsten Kobe;Jana Markova

  • TP53 Mutation and Survival in Chronic Lymphocytic Leukemia

    Thorsten Zenz;Barbara Eichhorst;Raymonde Busch;Tina Denzel

  • Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

    Kirsten Fischer;Jasmin Bahlo;Anna Maria Fink;Valentin Goede

  • First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.

    Barbara Eichhorst;Anna-Maria Fink;Jasmin Bahlo;Raymonde Busch

  • Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine

    Marc Beyer;Matthias Kochanek;Matthias Kochanek;Kamruz Darabi;Kamruz Darabi;Alexey Popov;Alexey Popov

  • COVID-19 associated pulmonary aspergillosis.

    Philipp Koehler;Oliver A. Cornely;Bernd W. Böttiger;Fabian Dusse

Frequent Co-Authors

Stephan Stilgenbauer
Stephan Stilgenbauer University of Ulm
Hartmut Döhner
Hartmut Döhner University of Ulm
Michael Kneba
Michael Kneba Kiel University
Raymonde Busch
Raymonde Busch Technical University of Munich
Peter Hillmen
Peter Hillmen St James's University Hospital
Hildegard Büning
Hildegard Büning Hannover Medical School
Thomas J. Kipps
Thomas J. Kipps University of California, San Diego
Martin Dreyling
Martin Dreyling Ludwig-Maximilians-Universität München
Paolo Ghia
Paolo Ghia Vita-Salute San Raffaele University
Andreas Engert
Andreas Engert University of Cologne

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine opens the door to a variety of other healthcare degrees and entry points. For those already working as registered nurses, affordable rn to bsn programs offer a flexible and cost-effective way to advance your nursing credentials online.

If you are switching careers and don’t have a nursing background, direct entry np programs for non nurses online allow motivated students to enter the nurse practitioner field quickly—even without prior experience.

Prospective students concerned about selectivity can look into nursing schools with high acceptance rates, which may provide greater opportunities for admission with less competitive entry requirements.

Alternatively, those interested in healthcare administration may consider medical billing and coding. If financial barriers are a concern, you might ask, can you get financial aid for medical billing and coding? Many accredited online programs offer support to make entering this field more accessible.

Best Scientists Citing Michael Hallek

Trending Scientists

Recently Published Articles